Congratulations to Mr Arie Parnham, Consultant Urologist at The Christie Hospital NHS Foundation Trust, who has been awarded a grant by The Urology Foundation part supported by the Charles Reynolds Foundation
This translational feasibility study will test a liquid biomarker based on a multi-modal molecular profile encompassing circulating HPV DNA, methylation changes and copy number alterations in cell free DNA for early detection of residual disease or recurrence following treatment of penile cancer.
Penile cancer is a rare cancer affecting the penis, which can have a significant impact on patient’s quality of life as well as their families. Many men feel isolated due to the lack of awareness in the community. Patients therefore usually present late by which time the disease may be fatal as current treatments are often ineffective. For those men who can potentially be cured, they are often left with significant side-effects because of their treatment. Despite these challenges, this disease has traditionally received limited research funding to identify potential ways to improve patient care.
The Charles Reynolds Foundation is proud to support his efforts and looks forward to the contributions this research will bring to the field.
Comments